Results 41 to 50 of about 19,757 (182)

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Sildenafil promotes osteogenic differentiation of human mesenchymal stem cells and inhibits bone loss by affecting the TGF-β signaling pathway

open access: yesStem Cell Research & Therapy
Background Osteoporosis, a common bone disorder, is primarily managed pharmacologically. However, existing medications are associated with non-trivial side-effects.
Menglong Hu   +9 more
doaj   +1 more source

Prenatal Sildenafil and Fetal-placental Programming in Human Pregnancies Complicated by Fetal Growth Restriction: A Retrospective Gene Expression Analysis

open access: yesJournal of Trial and Error, 2023
Objective: Fetal growth restricted (FGR) offspring are more susceptible to develop cardiovascular and renal disease. The potential therapeutic value of sildenafil to improve fetal growth has recently been evaluated in several randomized clinical trials ...
Fieke Terstappen   +9 more
doaj   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo   +7 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Effect of sildenafil in cavernous arteries of patients with erectile dysfunction

open access: yesInternational Brazilian Journal of Urology, 2003
INTRODUCTION: Sildenafil citrate is a type 5 phosphodiesterase inhibitor, which has demonstrated excellent results in the treatment of erectile dysfunction.
Joaquim A Claro   +5 more
doaj   +1 more source

Preoperative subcutaneous sildenafil injection increases random flap survival in rats [PDF]

open access: yesActa Cirúrgica Brasileira, 2018
Purpose: To investigate the effect of subcutaneous sildenafil on random flap survival. Methods: Fourteen Wistar rats, which were divided in to two groups, were used for this experimental study.
Merdan Serin   +6 more
doaj   +2 more sources

Stereoselective Construction of Benzo‐Fused Tetrahydropyrrole Thiazines From Saccharin

open access: yesEuropean Journal of Organic Chemistry, EarlyView.
Saccharin was used as a template to construct a series of 10a‐substituted, benzo‐fused, pyrrolo thiazinone dioxides. Thereafter, diastereo‐divergent 10‐keto reduction gave either diastereomeric alcohol in a process that did not rely on the substituent at 10a's identity.
Seanán Doyle   +8 more
wiley   +1 more source

Current practices in the use of sildenafil for pulmonary arterial hypertension in Brazilian hospitals

open access: yesBMC Research Notes, 2009
Background Sildenafil is a cyclic guanosine monophosphate-specific phosphodiesterase-5 inhibitor used for treating pulmonary hypertension. Although the use of sildenafil in patients under 18 years old is off-label, this inhibitor has been widely ...
Cabral Lucio M   +2 more
doaj   +1 more source

Sildenafil amplifies calcium influx and insulin secretion in pancreatic β cells

open access: yesPhysiological Reports
Sildenafil, a phosphodiesterase‐5 (PDE5) inhibitor, has been shown to improve insulin sensitivity in animal models and prediabetic patients. However, its other metabolic effects remain poorly investigated.
Naoya Murao   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy